IRVINE, Calif. (February 5, 2020) – JenaValve Technology, Inc., developer and manufacturer of the
JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of
aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital
Life Sciences. Additional participants in the financing included existing investors Andera Partners, Gimv,
Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. The Company
also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the
JenaValve Board of Directors.
“We are pleased to complete this financing led by new investor Bain Capital Life Sciences, a wellrespected name in healthcare, as well as strong participation from our existing venture investors,” said John Kilcoyne, JenaValve’s Chief Executive Officer. “This announcement comes on the heels of receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), which
allows for priority review of our Align Clinical Trial for the treatment of symptomatic, severe aortic
regurgitation (AR) and AR-dominant mixed aortic valve disease. Our TAVR system is differentiated in
that no other transcatheter valve device has FDA approval for patients suffering from severe AR who are
at high risk for surgery, which we believe is a multi-billion-dollar market opportunity. This financing
supports our ongoing clinical program and plans to file for U.S. Humanitarian Device Exemption (HDE)
approval in the second half of 2020.”
JenaValve is conducting a global multicenter clinical program for the treatment of patients with severe
AR and AR-dominant mixed aortic valve disease who are at high risk for surgery. Following completion
of the HDE portion of the trial, patient enrollment will continue in support of submitting a Premarket
Approval (PMA) application to the FDA under the Breakthrough Device program. The Company also
anticipates filing the JenaValve® for CE mark approval for both aortic stenosis and aortic regurgitation in
the second half of 2020.
“We welcome Dr. Hack to our Board and look forward to Bain Capital’s contribution to governance and
strategy,” added Mr. Kilcoyne. “Andrew’s industry knowledge and experience, as well as his success as
an institutional investor and chief financial officer will add valuable perspectives to our Board.”
Dr. Hack commented, “I’m delighted to join the JenaValve Board as the Company works to gain approval
for a solution to a significant unmet medical need. JenaValve’s focus on advancing a breakthrough
technology with the ability to improve patient lives embodies the characteristics we seek at Bain Capital
Life Sciences. We are committed to providing both financial assistance and oversight in support of
JenaValve’s success.”
Dr. Hack has served as a Managing Director at Bain Capital Life Sciences since 2019. He previously
served as Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) and as a healthcare portfolio
manager at Millennium Management. Prior to that, he was a securities analyst at a number of healthcarefocused hedge funds and investment banks. Dr. Hack received an MD and a PhD in molecular genetics
and cell biology from the University of Chicago.
About the JenaValve Transfemoral TAVR System
The JenaValve Pericardial TAVR System consists of a bioprosthesis comprised of a self-expanding nitinol
stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques.
The TAVR System is available in three sizes to treat a broad range of aortic annulus diameters.
The JenaValve Pericardial TAVR System is an investigational device, and is not available for sale in the
United States or internationally.
About Bain Capital Life Sciences
Bain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical,
specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies
globally. The team focuses on companies that both drive medical innovation across the value chain and
enable that innovation to improve the lives of patients with unmet medical needs. Since 1984, Bain
Capital has developed global reach, deep expertise and a proven track record in life sciences industries
across its Private Equity, Credit, Public Equity and Venture business units. Bain Capital Life Sciences
builds on the differentiated skillset and enables the firm to pursue opportunities created by several longterm trends in healthcare.
About JenaValve
JenaValve Technology, Inc., with locations in Irvine, Calif., Leeds, U.K. and Munich, Germany, develops
and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from
aortic valve disease. The Company is in clinical development of its next-generation transfemoral TAVR
system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic
regurgitation. In addition to Bain Capital Life Sciences, JenaValve is backed by European and Asian
investors, including Andera Partners (formerly Edmond de Rothschild Investment Partners), Gimv
(Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI
Partners. Additional information is available at www.jenavalve.com.
Investor and Media Contact:
Matt Clawson
W2Opure
(949) 370-8500
mclawson@w2ogroup.com
